Terms: = Ovarian cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
31 results:
1. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.
Guan HR; Li B; Zhang ZH; Wu HS; He XL; Dong YJ; Su J; Lv GY; Chen SH
BMC Complement Med Ther; 2023 Dec; 23(1):458. PubMed ID: 38102584
[TBL] [Abstract] [Full Text] [Related]
2. 3'-Hydroxypterostilbene Potently Suppresses Tumor Growth via Inhibiting the Activation of the jak2/STAT3 Pathway in ovarian Clear Cell Carcinoma.
Koh YC; Huang WZ; Nagabhushanam K; Ho CT; Pan MH
Mol Nutr Food Res; 2024 Jan; 68(1):e2300108. PubMed ID: 37876143
[TBL] [Abstract] [Full Text] [Related]
3. Ginkgetin suppresses ovarian cancer growth through inhibition of jak2/STAT3 and MAPKs signaling pathways.
Wu L; Qian C; Zhang W; Shi M; Chen X; Wang Y; Lin F
Phytomedicine; 2023 Jul; 116():154846. PubMed ID: 37172479
[TBL] [Abstract] [Full Text] [Related]
4. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
5. Hyperandrogenism due to ovarian Leydig cell tumour presenting with polycythaemia.
Demir AY; Blok BB; Brinkhuis EA; Oldenburg-Ligtenberg CP
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35840164
[TBL] [Abstract] [Full Text] [Related]
6. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
7. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
8. SENP1-mediated deSUMOylation of jak2 regulates its kinase activity and platinum drug resistance.
Li J; Wu R; Yung MMH; Sun J; Li Z; Yang H; Zhang Y; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Zheng W; Wei H; Gao Y; Nemes P; Pei H; Chan DW; Li Y; Zhu W
Cell Death Dis; 2021 Apr; 12(4):341. PubMed ID: 33795649
[TBL] [Abstract] [Full Text] [Related]
9. Triptolide inhibits jak2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
[TBL] [Abstract] [Full Text] [Related]
10. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting jak2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract] [Full Text] [Related]
11. [High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of Leukemia Cells to the Antibiotic Mithramycin].
Vagapova ER; Lebedev TD; Tikhonova AD; Goikhman BV; Ivanenko KA; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2020; 54(3):522-528. PubMed ID: 32492016
[TBL] [Abstract] [Full Text] [Related]
12. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
[TBL] [Abstract] [Full Text] [Related]
13. Autocrine activation of jak2 by IL-11 promotes platinum drug resistance.
Zhou W; Sun W; Yung MMH; Dai S; Cai Y; Chen CW; Meng Y; Lee JB; Braisted JC; Xu Y; Southall NT; Shinn P; Huang X; Song Z; Chen X; Kai Y; Cai X; Li Z; Hao Q; Cheung ANY; Ngan HYS; Liu SS; Barak S; Hao J; Dai Z; Tzatsos A; Peng W; Pei H; Han Z; Chan DW; Zheng W; Zhu W
Oncogene; 2018 Jul; 37(29):3981-3997. PubMed ID: 29662190
[TBL] [Abstract] [Full Text] [Related]
14. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/jak2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract] [Full Text] [Related]
15. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.
Chen KE; Bustamante K; Nguyen V; Walker AM
Oncotarget; 2017 May; 8(22):36368-36382. PubMed ID: 28422740
[TBL] [Abstract] [Full Text] [Related]
16. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract] [Full Text] [Related]
17. ovarian cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1.
Jung JG; Shih IM; Park JT; Gerry E; Kim TH; Ayhan A; Handschuh K; Davidson B; Fader AN; Selleri L; Wang TL
Cancer Res; 2016 Nov; 76(21):6351-6361. PubMed ID: 27590741
[TBL] [Abstract] [Full Text] [Related]
18. Stress-induced phosphoprotein-1 maintains the stability of jak2 in cancer cells.
Tsai CL; Chao A; Jung SM; Tsai CN; Lin CY; Chen SH; Sue SC; Wang TH; Wang HS; Lai CH
Oncotarget; 2016 Aug; 7(31):50548-50563. PubMed ID: 27409672
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of jak2 Reverses Paclitaxel Resistance in Human ovarian cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract] [Full Text] [Related]
20. XCR1 promotes cell growth and migration and is correlated with bone metastasis in non-small cell lung cancer.
Wang T; Han S; Wu Z; Han Z; Yan W; Liu T; Wei H; Song D; Zhou W; Yang X; Xiao J
Biochem Biophys Res Commun; 2015 Aug; 464(2):635-41. PubMed ID: 26166822
[TBL] [Abstract] [Full Text] [Related]
[Next]
